News

EU Award for Gender Equality Champions third edition open for submissions

Published on | 5 months ago

Programmes Enhancing EU R&I Horizon Europe

The EU Award for Gender Equality Champions was created under Horizon Europe to recognise the results achieved by academic and research organisations in the implementation of gender equality plans (GEPs). GEPs is an eligibility criterion for all public bodies, higher education institutions and research organisations from EU Member States and associated countries wishing to participate in Horizon Europe. The eligibility criterion was introduced for calls with deadlines in 2022 and onwards.

The award is open to universities, higher education institutions, and other research performing organisations (public or private), established in an EU Member State or a non-EU country associated to Horizon Europe.

There are three categories: Sustainable, Newcomer and Inclusive. Deadline to apply is 16 October 17:00 CET. The evaluation is expected to be finalized by March 2025. Each winner will receive a €100,000 prize: one in the sustainable and inclusive categories and two in newcomer category.

Interested to apply for this recognition prize? Find out more about the general and specific conditions via the call topic pages on the European Commission Funding and Tenders Portal:  

More information on the aims, categories and application process is also available on the DG R&I EU Award for Gender Equality Champions page.

To find out more about the impact of gender equality plans across the European Research Area consult this factsheet and seven policy briefs which have been published ahead of the publication of the main report on the topic.

myOverview - sign up for personalised information

We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).

Stay informed about what matters to you. By signing up, you can opt in for e-mail notifications and get access to a personalised dashboard that groups all news updates and event announcements in your domain(s).

Only for stakeholders located in Flanders

Latest News

1530 articles available search in articles 

Testimonial

image of Methylomic – Hope & Improved outcomes for Crohn’s disease patients across Europe

Methylomic – Hope & Improved outcomes for Crohn’s disease patients across Europe

The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.